Oodles of shares issued at just 45.77p: |
Ahh - in stumbles 1347 like the drunken village idiot. Still shouting about yer sub 40p sp? Thought not. |
Death spriral loan conversion due tomorrow, are they going to pay in cash? Personally I doubt it and it looks like it was already foward sold in that last little mini spike. Remind me, when in 2024 is Phase II of AVA6000 starting? |
Amaan, you still waiting for the mid 30's before you buy back in again? |
"I would go one step further and question if any of their efficacy results showed any tumour shrinkage at all."
Sorry, but that implies fraudulent reporting, which you have categorically said is NOT the case? (on numerous occassions). Are you changing your tune on this? |
King Suarez - "PW is saying, as he keeps maintaining, that DOX is not being released at all by AVA6K and that any of the efficacy results being show are in line with the random chance that some tumours shrink of their own accord."
That's exactly what I'm saying and why the safety record is 100% at all dosage levels. I would go one step further and question if any of their efficacy results showed any tumour shrinkage at all. |
Absolutely vertizeasun .
Just the financial so called,’death spiral,hanging over the finance . |
"It's telling us that 90% of the people who took this drug saw their #cancer tumour growth halted in its tracks and 50% of them are seeing tumours SHRINK
These patients are end of life, and are heavily pre-treated with metastatic cancers, basically it's as bad as it can get. They've exhausted all other options, their cancers have built up resistance to treatments so they're just waiting to DIE. Seeing ANY efficacy at all is a miracle, given this is just a safety trial - yet here we are." |
You could write a book about the Avacta story or maybe someone will make a film. On this thread we have a mixture of LTHs, Traders, shorters, those who think it doesn't work while over on LSE there's now a new line of FUD saying it works too well. Laughable. |
Closed short today, 51 (posn 74).
I'll await the death spiral. |
Oh and to top it off out the blue on x mc pumpy dumpy, not to be be seen over the last quarter but all of a sudden ?lord have mercy, it's almost like it's predictable ? |
So what would you do then Jaknife: release news at the best possible time for the company finances or the worst possible time? BTW why are you here? |
King Suarez back ie Rajraj funny as ...the tag team delight. |
Who knows the secret of the black box? |
Almost certainly... |
Is there a conversion coming on the death spiral by any chance? |
Zak Mir view
“Comment: This is clearly a worthy and significant breakthrough by AVCT. The issue for shareholders is which particular breakthrough / RNS will get the big re-rate so many of them are waiting for in the stock.” |
"Are you saying that dox does not work?"
PW is saying, as he keeps maintaining, that DOX is not being released at all by AVA6K and that any of the efficacy results being show are in line with the random chance that some tumours shrink of their own accord.. |
Well, Fieldhouse and Cheshire ... genuinely surprised at that market reaction. Well done, at least for now. |
This worm will turn and evolve into a gazelle or something similar. Perhaps 2025 is the year. |
We are all ‘doomed’, ‘all doomed’. The plague returns ! |
Whitey: ..."because it (the drug) does not work". My understanding is that AVA6000 is not a drug per se but a delivery system that allows standard dox to work with significantly reduced side effects. Are you saying that dox does not work?
The RNS seemed very positive to me. LTH and not day trading Avacta, so happy to await developments. |
I'm afraid this is pretty much a re-hash of results that have been drip fed out since 19th September 2023 (likely done now to help with the next death spiral loan conversion in a few days).
Still only a very few confirmed significant responses and I note that they now focus on a subset of just the 10 patients with SGC dosed at 250 mg/m2 and above, not out of the total of 57 patients thus far, I suspect this is to make it look better.
The first patient was dosed on 11th August 2021 so that's now three and a half years and all we can conclude after all that time is that it's safer at higher doses and thus possibly a bit more effective than standard dox. So when's the Phase II, it should have started in 2024? Apart from AVA6000 all they have now are the back to the drawing board pre-clinical candidates. |
"Based on this favorable efficacy and safety data observed in the Phase 1a trial, Avacta has initiated three Phase 1b expansion cohorts"
Going into the fifth year now at Phase 1. The only thing that is guaranteed is that the drug is 100% safe at all dosage levels and that's because it does not work. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
